Description
Product Overview: CJC-1295 (No DAC) + Ipamorelin Blend
The CJC-1295 (No DAC) + Ipamorelin Blend is a co-formulated dual-peptide matrix combining a Growth Hormone-Releasing Hormone (GHRH) analog with a selective Growth Hormone Secretagogue (GHS). **CJC-1295 (No DAC)** (Modified GRF 1-29) acts on pituitary somatotroph GHRH receptors, while **Ipamorelin** selectively targets ghrelin receptors (GHS-R1a). By co-activating these two independent neuroendocrine signaling pathways simultaneously, this combination produces a highly synergistic, supra-additive release of endogenous Growth Hormone (GH) that mirrors natural physiological pulsing without elevating baseline cortisol or prolactin.
Primary Research Applications & Reasons for Study
- Dual-Pathway Somatotroph Synergy: Investigating the multi-receptor cascade triggered by concurrent GHRH and GHS-R1a activation to measure amplified, natural GH amplitude.
- Pulsatile Secretion & Axis Safety: Modeling short-acting, physiological growth hormone surges that return to baseline naturally without causing continuous GH elevation or pituitary desensitization.
- Adipose Metabolism & Nitrogen Balance: Assessing downstream hepatic IGF-1 expression, nitrogen retention in muscle models, and accelerated lipolysis in fat tissue assays.
- Tissue Repair & Bone Density: Evaluating osteoblast proliferation, collagen matrix remodeling, and microvascular density growth in musculoskeletal recovery models.
Expected Research Results & Timeline Metrics
-
Phase 1 / Minutes 15–45
Synergistic GH Spike: Simultaneous GHRH and GHS-R1a binding produces an immediate, supra-additive growth hormone pulse, peaking within 30 minutes of administration. -
Phase 2 / Weeks 1–3
IGF-1 & Metabolic Shift: Statistically significant upregulation of circulating serum IGF-1 levels, heightened fatty acid oxidation, and improved cellular nitrogen retention markers. -
Phase 3 / Weeks 4–8+
Compositional & Connective Adaptations: Measurable reductions in total body fat mass, enhanced collagen synthesis in tendons/ligaments, and optimized bone mineral accretion without altering baseline thyroid or adrenal markers.
Key Research Benefits
- True Supra-Additive Synergy: Combining GHRH and GHS-R1a agonists yields significantly higher GH pulse amplitudes than administering either peptide individually.
- High Hormonal Selectivity: Triggers clean GH pulses without stimulating cortisol, ACTH, prolactin, or appetite-inducing central pathways.
- Natural Pulsatile Kinetics: Absence of the Drug Affinity Complex (No DAC) allows for tight, short-acting pulses that honor natural somatostatin feedback mechanisms.
- Gold-Standard Combination Standard: Widely accepted as the benchmark dual-peptide secretagogue stack in endocrine and anti-aging research.
THIS PRODUCT IS INTENDED SOLELY FOR IN VITRO LABORATORY RESEARCH AND EXPERIMENTAL PURPOSES. It is strictly prohibited for human consumption, clinical trials, therapeutic administration, cosmetic use, or veterinary application. This product is not an FDA-approved drug, medical food, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease, illness, or medical condition. Any handling, reconstitution, or experimentation involving this chemical compound must be conducted strictly by qualified, trained laboratory professionals utilizing appropriate containment and personal protective equipment in accordance with scientific biosafety standards. Buyers and users assume full liability for compliance with local, state, and federal laws regarding the handling and possession of research compounds.